SCHEMBL6316611

SCHEMBL6316611

Nc1onc(-c2ccc(-c3cccc(Cl)c3)o2)c1C(=O)NCc1cccc(Cl)c1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.48
ALDH1A1 P00352 2/20 0.48
MAPT P10636 1/20 0.45
POLB P06746 1/20 0.45
ADORA1 P30542 2/20 0.44
ADORA3 P0DMS8 1/20 0.44
ADORA2A P29274 1/20 0.44
ADORA2B P29275 1/20 0.44
SLC9A1 P19634 1/20 0.43
NPC1 O15118 1/20 0.43
GAA P10253 1/20 0.42
TP53 P04637 2/20 0.41
S1PR4 O95977 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA4 P22748 1/20 0.41
CA7 P43166 1/20 0.41
LMNA P02545 1/20 0.41
THRB P10828 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6318222 0.93 ALDH1A1 (0.44) RAB9AALDH1A1MAPTPOLBADORA1
SCHEMBL6318549 0.92 RAB9A (0.46) RAB9AALDH1A1MAPTPOLBSLC9A1
SCHEMBL6317377 0.91 LMNA (0.48) RAB9AALDH1A1MAPTADORA1GAA
SCHEMBL6324730 0.91 HPGD (0.46) RAB9AALDH1A1MAPTPOLBADORA1
SCHEMBL6323615 0.90 MAPT (0.56) RAB9AALDH1A1MAPTSLC9A1NPC1
SCHEMBL6323008 0.90 CA1 (0.52) MAPTADORA1ADORA3ADORA2AADORA2B
SCHEMBL6320762 0.88 HCRTR1 (0.51) RAB9AALDH1A1MAPTLMNA
SCHEMBL6318194 0.88 MEN1 (0.53) RAB9AALDH1A1MAPTPOLBNPC1
SCHEMBL6316618 0.88 TACR1 (0.46) RAB9AALDH1A1POLBGAALMNA
SCHEMBL6317733 0.88 RAB9A (0.45) RAB9AALDH1A1MAPTPOLBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 RAB9A 1754/4885ALDH1A1 4444/4885MAPT 281/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.